Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $360.03 | Prev. Close $355.37 | Circuit Range N/A |
Day Range $339.12 - $360.03 | Year Range $130.50 - $382.01 | Volume 20,056 |
Average Traded $344.30 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jul-26 | $360.03 | $339.21 | +0.00% |
20-Jul-26 | $360.03 | $339.21 | -4.35% |
17-Jul-26 | $337.24 | $354.63 | +3.81% |
16-Jul-26 | $349.41 | $341.61 | -2.45% |
15-Jul-26 | $329.37 | $350.18 | +3.10% |
14-Jul-26 | $362.90 | $339.64 | -6.61% |
13-Jul-26 | $364.02 | $363.69 | -0.52% |